3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
18
Parkinson Disease 4, Autosomal Dominant Lewy Body
6
Breast Neoplasms
6
Metastatic Castration-resistant Prostate Cancer
3
Fallopian Tube Neoplasms
3
Triple Negative Breast Neoplasms
2
Neoplasm Metastasis
2
Endometrial Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Carcinoma
2
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Prostatic Neoplasms
1
Peritoneal Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Neoplasms
1
Lung Neoplasms
1
Hematologic Neoplasms
1
HER2-ve Metastatic Breast Cancer
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cyclophosphamide
3
Epirubicin
2
Docetaxel
2
Carboplatin
2
Capecitabine
2
Azacitidine
2
venetoclax
1
tegafur-gimeracil-oteracil
1
taxane
1
sargramostim
1
ruxolitinib
1
rucaparib
1
pirarubicin
1
pertuzumab
1
pembrolizumab
1
olaparib
1
cc-486
1
Trastuzumab
1
Thalidomide
1
Radiotherapy
1
Radiation
1
Platinum
1
Paclitaxel
1
Oxaliplatin
1
Observation
1
Nivolumab
1
Monatide (IMS 3015)
1
Methotrexate
1
Magnetic Resonance Imaging
1
Leucovorin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Pathologic Complete Response
×
olaparib
×
Clear all
NCT01844986
2025-12-10
SOLO-1
AstraZeneca
Phase 3
Active not recruiting
450 enrolled
18 charts
1 FDA